TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES

被引：0
|
作者：
Pirro, V. [1 ]
Nikooienejad, A. [1 ]
Lin, Y. [1 ]
Willency, J. [1 ]
Wilson, J. [1 ]
Duffin, K. [1 ]
Robins, D. [1 ]
Milicevic, Z. [1 ]
Haupt, A. [1 ]
Thomas, M. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
DIABETES TECHNOLOGY & THERAPEUTICS | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P232 / #49
引用
收藏
页码：A165 / A165
页数：1
相关论文
共 50 条
  • [1] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
  • [2] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan M.
    Duffin, Kevin L.
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    DIABETES, 2019, 68
  • [3] Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients
    Thomas, M. K.
    Nikooienejad, A.
    Bray, R.
    Cui, X.
    Wilson, J.
    Duffin, K.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S354 - S354
  • [4] Retatrutide, an Agonist of GIP, GLP-1, and Glucagon Receptors, Improves Markers of Pancreatic Beta-Cell Function and Insulin Sensitivity
    Rosenstock, Julio
    Coskun, Tamer
    Hartman, Mark L.
    Lou, Jitong
    Wu, Qiwei
    Du, Yu
    Gurbuz, Sirel
    Mather, Kieren J.
    Milicevic, Zvonko
    Thomas, Melissa K.
    DIABETES, 2024, 73
  • [5] Retatrutide, an agonist of GIP, GLP-1, and glucagon receptors, improves markers of pancreatic beta cell function and insulin sensitivity
    Thomas, M. K.
    Rosenstock, J.
    Coskun, T.
    Hartman, M. L.
    Lou, J.
    Wu, Q.
    Du, Y.
    Gurbuz, S.
    Mather, K.
    Milicevic, Z.
    DIABETOLOGIA, 2024, 67 : S72 - S73
  • [6] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    CIRCULATION, 2020, 142
  • [7] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
    Wong, Elaine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
  • [8] Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy improved markers of islet cell function and insulin sensitivity in people with type 2 diabetes (SURPASS-1)
    Lee, C. J.
    Thieu, V. T.
    Mao, H.
    Thomas, M. K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 245 - 246
  • [9] The dual GIP/GLP-1 receptor agonist tirzepatide improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
    Wilson, J. M.
    Nikooienejad, A.
    Bowsman, L. M.
    Schroeder, J. M.
    Hamlin, D. M.
    Robins, D. A.
    Riesmeyer, J. S.
    Haupt, A.
    Duffin, K. L.
    Ruotolo, G.
    DIABETOLOGIA, 2019, 62 : S558 - S559
  • [10] Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
    Willard, Francis S.
    Douros, Jonathan D.
    Gabe, Maria
    Showalter, Aaron D.
    Wainscott, David B.
    Suter, Todd M.
    Capozzi, Megan E.
    van der Velden, Wijnand J. C.
    Stutsman, Cynthia
    Cardona, Guemalli R.
    Urva, Shweta
    Emmerson, Paul J.
    Holst, Jens J.
    D'Alessio, David A.
    Coghlan, Matthew P.
    Rosenkilde, Mette M.
    Campbell, Jonathan E.
    Sloop, Kyle W.
    JCI INSIGHT, 2020, 5 (17)
12345